drugset / Trial / NCT02467361
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, multi-center, Phase 1/2 study of BBI608 administered in combination with immunotherapy in adult patients with advanced cancers. The goal of the study is to determine the RP2D of BBI608 in combination with each of the immunotherapeutic agents.
Timeline
- Start
- 2015-08
- Primary completion
- 2021-01-29
- Completion
- 2021-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Napabucasin | Small molecule | 240 mg | — |
| Subject | Napabucasin | Small molecule | 480 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 2 mg/kg | Intravenous |